Disulfiram boosts the efficacy of anti-PD-1 therapy TNBC by influencing PD-L1 expression. This occurs via the epigenetic reactivation of IRF7, a key regulator of immune signaling, which enhances the tumor’s responsiveness to immune checkpoint blockade therapy. This evidence concerns the gene IRF7 and neoplasm.